Founded in 2008 and headquartered in Lenexa, Kan., AxelaCare is a leading high-growth technology-enabled provider of home infusion services. The company is a full-service provider of chronic therapies, particularly immune globulin (IG) therapy, and acute infusion therapies, such as antibiotics and total parenteral nutrition (TPN). AxelaCare is the fifth largest provider of IG therapy in the U.S. and continues to grow several times faster than the industry. AxelaCare partnered with Harvest Partners in April 2013.

SCPSI, founded in 2010 with the acquisition of Sirona Infusion, has grown organically and through acquisitions to become a premier provider of acute home infusion services in the Southwest, West, and Northwestern markets. Its network of pharmacies, infusion centers, and nursing staff spans Arizona, New Mexico, California, Colorado, and Oregon. Therapies delivered include the full spectrum of acute and chronic infusion therapies, including anti-infective, oncolytic, TPN, cardiac, hydration, and other intravenously delivered medicines.

The acquisition of SCPSI will double the number of pharmacies operated by AxelaCare, which are located in 10 states across the U.S., with additional locations scheduled to open in new states in the next two quarters. Local pharmacies increase responsiveness to acute infusion service needs as well as broaden market coverage for national managed care accounts.

Houlihan Lokey served as financial advisor to AxelaCare. Our Healthcare Group is a recognized leader in M&A advisory and capital-raising services, providing advice to healthcare services, managed care, healthcare IT, and life sciences companies. With more than 25 investment bankers in Chicago, Dallas, Minneapolis, and San Francisco, our group is among the largest dedicated healthcare investment banking groups in the country. Houlihan Lokey's Healthcare Group has closed more than 50 transactions since 2010.

Houlihan Lokey is an international investment bank with expertise in mergers and acquisitions, capital markets financial restructuring, and valuation. The firm serves corporations, institutions, and governments worldwide with offices in the United States, Europe, and Asia. Independent advice and intellectual rigor are hallmarks of our commitment to client success across our advisory services. Houlihan Lokey is ranked globally as the No. 1 restructuring advisor, the No. 1 M&A fairness opinion advisor over the past 10 years, and the No. 1 M&A advisor for U.S. transactions under $3 billion, according to Thomson Reuters.

If you would like more information about Houlihan Lokey, or if you have any questions regarding our role in this transaction, please contact the deal team member listed.